Personal CFO Solutions LLC Grows Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Personal CFO Solutions LLC boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report) by 6.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,574 shares of the medical instruments supplier’s stock after buying an additional 336 shares during the quarter. Personal CFO Solutions LLC’s holdings in LeMaitre Vascular were worth $316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in LMAT. DekaBank Deutsche Girozentrale purchased a new position in shares of LeMaitre Vascular in the third quarter valued at $38,000. SRS Capital Advisors Inc. grew its position in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares in the last quarter. Campbell & CO Investment Adviser LLC grew its position in shares of LeMaitre Vascular by 78.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 5,329 shares of the medical instruments supplier’s stock valued at $290,000 after purchasing an additional 2,349 shares in the last quarter. KLR Investment Advisors LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter valued at $351,000. Finally, Riverwater Partners LLC grew its position in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 198 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bridget A. Ross sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total value of $428,945.00. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $177,661.22. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $77.99, for a total value of $428,945.00. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $177,661.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,431 shares of company stock valued at $6,627,520. Insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LMAT shares. Roth Mkm reissued a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Barrington Research lifted their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

View Our Latest Stock Analysis on LeMaitre Vascular

LeMaitre Vascular Stock Up 0.2 %

Shares of LMAT stock opened at $77.65 on Tuesday. The business has a 50-day moving average price of $71.81 and a two-hundred day moving average price of $64.04. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $81.68. The firm has a market cap of $1.74 billion, a P/E ratio of 51.42, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The company’s revenue was up 13.6% compared to the same quarter last year. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Recommended Stories

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.